The DOI matches its Crossref record.
Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome.
Abstract
A major sequela of immunotherapy with interleukin 2 (IL-2) is development of a vascular leak syndrome. The pathogenesis of this toxic effect is not known. We have examined pre- and post-treatment skin biopsies from 14 patients undergoing systemic administration of IL-2 for evidence of endothelial cell activation. Specifically, we have used the immunoperoxidase technique to detect the expression of three different activation antigens: endothelial-leukocyte adhesion molecule 1, detected with monoclonal antibody H4/18; intercellular adhesion molecule 1, detected with antibody RR1/1; and histocompatibility leukocyte antigen-DQ, detected with antibody Leu 10. Each of these antigens may be induced on cultured endothelial cells by various cytokines (although not by IL-2) and is expressed during endothelial cell activation in vivo at sites of delayed hypersensitivity and other immune responses. Pretreatment biopsies from each patient showed no endothelial expression of endothelial-leukocyte adhesion molecule 1 and only weak to moderate expression of intercellular adhesion molecule 1 and histocompatibility leukocyte antigen-DQ (except for one specimen unreactive with Leu 10). After 5 days of treatment, every patient showed marked endothelial expression of all three antigens (except for the same patient who remained unreactive with Leu 10). Endothelial-leukocyte adhesion molecule-1 expression was confined to postcapillary venular endothelium whereas intercellular adhesion molecule-1 and Leu 10 also were expressed on stromal cells and mononuclear cells. Thus, we conclude that i.v. administration of IL-2 leads to endothelial cell activation. Because IL-2 fails to induce the same antigens on cultured endothelial cells, we infer that IL-2 acts in vivo by inducing the production of other cytokines (e.g., interleukin 1, tumor necrosis factor, lymphotoxin, and interferon-gamma). Finally, since endothelial cell activation at sites of cell-mediated immune responses is well known to result in vascular leakiness to macromolecules, we propose that the vascular leak syndrome accompanying IL-2 therapy may arise from widespread inappropriate endothelial cell activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During Atherogenesis
Cybulsky, M. I., & Gimbrone, M. A. (1991) · Science · doi:10.1126/science.1990440 · Cited by 1,712
Self-citationMarlin, S. D., & Springer, T. A. (1987) · Cell · doi:10.1016/0092-8674(87)90104-8 · Cited by 1,674
Self-citationDustin, M. L., & Springer, T. A. (1988) · The Journal of cell biology · doi:10.1083/jcb.107.1.321 · Cited by 985
Self-citationAn Inducible Endothelial Cell Surface Glycoprotein Mediates Melanoma Adhesion
Rice, G. E., & Bevilacqua, M. P. (1989) · Science · doi:10.1126/science.2588007 · Cited by 641
Holler, E., Kolb, H., Moller, A., Kempeni, J., Liesenfeld, S., Pechumer, H., Lehmacher, W., Ruckdeschel, G., Gleixner, B., & Riedner, C. (1990) · Blood · doi:10.1182/blood.v75.4.1011.1011 · Cited by 577
Kishimoto, T. K., Larson, R. S., Corbi, A. L., Dustin, M. L., Staunton, D. E., & Springer, T. A. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60653-7 · Cited by 524
Self-citationT Cell Deletion in High Antigen Dose Therapy of Autoimmune Encephalomyelitis
Critchfield, J. M., Racke, M. K., Zúñiga-Pflücker, J. C., Cannella, B., Raine, C. S., Goverman, J., & Lenardo, M. J. (1994) · Science · doi:10.1126/science.7509084 · Cited by 524
Griffiths, C. E. M., Voorhees, J. J., & Nickoloff, B. J. (1989) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(89)70073-6 · Cited by 498
Siegel, J. P., & Puri, R. K. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.694 · Cited by 465
Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer.
Rosenberg, S. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.2.180 · Cited by 390
Self-citationLeung, D. M., Kurt-Jones, E., Newburger, J., Cotran, R., Burns, J., & Pober, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91910-7 · Cited by 381
Self-citationTUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER
Kradin, R., Lazarus, D., Dubinett, S., Gifford, J., Grove, B., Kurnick, J., Preffer, F., Pinto, C., Davidson, E., Callahan, R., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91609-7 · Cited by 336
Natural history and therapy of metastatic renal cell carcinoma: The role of interleukin-2
Bukowski, R. M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971001)80:7<1198::aid-cncr3>3.0.co;2-h · Cited by 325
Kurane, I., Innis, B. L., Nimmannitya, S., Nisalak, A., Meager, A., Janus, J., & Ennis, F. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115457 · Cited by 312
Delivering safer immunotherapies for cancer
Milling, L., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 305
Vascular leak syndrome: a side effect of immunotherapy
Baluna, R., & Vitetta, E. S. (1997) · Immunopharmacology · doi:10.1016/s0162-3109(97)00041-6 · Cited by 280
Forecasting the cytokine storm following systemic interleukin (IL)-2 administration
Panelli, M. C., White, R., Foster, M., Martin, B., Wang, E., Smith, K., & Marincola, F. M. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-17 · Cited by 139
Metadata
- Authors
- Cotran, R. S., Pober, J. S., Gimbrone, M. A., Springer, T. A., Wiebke, E. A., Gaspari, A. A., Rosenberg, S. A., & Lotze, M. T.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1988-03
- Volume
- 140
- Issue
- 6
- Pages
- 1883-1888
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2155906863
- Cited by
- 221
- References
- 0
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.